Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

ANALYSIS OF THE RANGE OF DRUGS USED FOR DIABETES

DOI: https://doi.org/10.29296/25877313-2020-06-02
Download full text PDF
Issue: 
6
Year: 
2020

N.R. Pavets Post-graduate Student, All-Russian ScientificResearch Institute of Medicinal and Aromatic Plants (Moscow) M.A. Dzhavakhyan Dr.Sc. (Pharm.),Associate Professor, Chief Research Scientist, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants(Moscow) E-mail: akopovamarina13@mail.ru

According to the State Register of Diabetes Patients, as of January 2015, in the Russian Federation, there are 4.04 million patients in terms of access to medical institutions: type 1 diabetes  340 thousand and type 2 diabetes = 3.7 million (the most common type 2 diabetes) count. However, these fig-ures are considered according to the results of the control and epidemiological studies conducted by the Endocrinological Research Center (ENC) of the Ministry of Health of the Russian Federation in the period from 2002 to 2010, do not reflect the true picture. The number of patients with diabetes in Russia is approximately 3-4 times more than officially registered and reaches 9-10 million people, which is about 7% of the population. Currently, diabetes mellitus (DM) is the most common among endocrinological diseases. The growth in the number of diabetes diseases over the past 10 years has doubled and amounted to 387 million people. According to the forecasts of the International Diabetes Federation, by 2035 592 million people will suffer from diabetes.
Keywords: 
diabetes mellitus (DM)
insulin
drugs
nomenclature analysis

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Yarkova N.A., Borovkov N.N., Zanozina O.V. Osnovy lecheniya sakharnogo diabeta. N.Novgorod: Izd-vo Nizhegorodskoi gosudarstvennoi meditsinskoi akademii. 2016. 52 s.
  2. Federalnyi registr bolnykh sakharnym diabetom. http://diaregistry.ru/zapros 20.10.2019.
  3. Yarkova N.A., Borovkov N.N., Zanozina O.V. Osnovy lecheniya sakharnogo diabeta. Novgorod: Izd-vo Nizhegorodskoi gosudarstvennoi meditsinskoi akademii. 2016.
  4. Kotov S.V., Kalinin A.P., Rudakova I.G. Diabeticheskaya neiropatiya. M.: OOO «Izd-vo «Meditsinskoe informatsionnoe agentstvo». 2011.
  5. International Diabetes Federation. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/134-idf-diabetes-atlas-8th-edition.html/Zapros 20.10.19.
  6. Kalyagin A.N. Khronicheskaya serdechnaya nedostatochnost: sovremennoe ponimanie problemy. Osobennosti vedeniya bolnykh s sakharnym diabetom (soobshchenie 17). Sibirskii meditsinskii zhurnal (Irkutsk). 2008; 80(5): 93–99.
  7. Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association. https://care.diabetesjournals.org/content/37/supplement_1/s81.short, 2014. Запрос от 25.01.2020.
  8. Haidar A., Legault L., Messier V., Mitre T.M., Leroux C., Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Thelancet Diabetes & endocrinology. 2015. 3(1): 17–26.
  9. Gosudarstvennyi reestr lekarstvennykh sredstv. https://grls.rosminzdrav.ru/ zapros от 20.10.19.
  10. Ponomarenko E.V., Kotegov V.P. Experimental research abilities guacarben to reduce atherogenic fats of blood. RUDN Journal of Medicine. 2009; 4: 234–236.
  11. Kvasova T.M. Vliyanie preparatov sbora Arfazetin na techenie experimentalnogo sakharnogo diabeta u krys.Vrach-aspirant. 2011; 48(5.1.): 157–162.
  12. Korotkova V.D., Prerlygina A.A., Trumpe T.E. Arfazetin v lechenii sakharnogo diabeta. Problemy endokrinilogii. 1988. 34(4): 25.
  13. Kvasova T.M. Issledovanie soderzhaniya polisakharidov v preparatakh sbora «Arfazetin» i otdelnykh ego komponentakh. Aktualnye problem gumanitarnykh i estestvennykh nauk. 2011; 8: 157–160.
  14. Gavrilin M.V., Senchenko S.P. Ispolzovanie kapilyarnogo elektroforeza dlya kolichestvennogo opredeleniya fenolnykh soedinenii v sbore «Arfazetin». Voprosy biologicheskoi, meditsinskoi i farmatsevticheskoi khimii. 2009; 7(5): 55–57.
  15. Morozova V.E., Makarova V.E., Pogorelyi V.E., Mecnikova G.Ya., Stepanova T.A. Izuchenie gipoglikemicheskoi i glyukozuricheskoi aktivnosti nastoev cherniki pazushnoi, cherniki volosistoi i golubiki. Dalnevostochnyi meditsinskii zhurnal. 2005;1: 67–70.
  16. Dzhafarova R.E., Garaev G.Sh., Dzhafarkulieva Z.S. Deistviya ekstrakta listev cherniki obyknovennoi na techenie patologicheskogo protsessa alloksan-indutsirovannogo sakharnogo diabeta. Fundamentalnye issledovaniya. 2010; 4: 36–43.
  17. Sedova A.B., Lipatnikova I.A., Yushkova T.A. Farmakologicheskie issledovaniya granul na osnove protivodiabeticheskogo sbora «Farmitin». Elektronnyi naucno-obrazovatelnyi vestnik «Zdorove i obrazovanie v XXI veke». 2017; 19(9): 180–182.